Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Jeffrey S. Weber(NYU Langone Health), Ana Arance(Hospital Clínic de Barcelona), Mario Mandalà(University of Perugia), Luis de la Cruz‐Merino, Michele Maio(University of Siena), Leslie A. Fecher(University of Pennsylvania), C. Lance Cowey(Texas Oncology), Michael Schenker(Sorbonne Université), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Petr Arenberger(Charles University), Mark R. Middleton(University of Oxford), Veerle de Pril(Inserm), Nikhil I. Khushalani(Roswell Park Comprehensive Cancer Center), Maurice Lobo(Bristol-Myers Squibb (United States)), Andrew Hill(University of Auckland), Iván Márquez‐Rodas(Hospital General Universitario Gregorio Marañón), Paola Queirolo, Stéphane Dalle(Hospices Civils de Lyon), James Larkin(Trinity College Dublin), Michael Millward(The University of Western Australia), Helen Gogas(National and Kapodistrian University of Athens), John T. Loffredo(Bristol-Myers Squibb (United States)), Victoria Atkinson(Greenslopes Private Hospital), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Jean-Jacques Grob(Aix-Marseille Université), Marcus O. Butler(University of Toronto)
Cited by 530
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k